Firebrick Pharma Limited
Firebrick Pharma Limited
Your view on FRE.AX
Overview
What the company does, where it operates, and who runs it.
About Firebrick Pharma Limited
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Peter Laurence Molloy
- Headquarters
- Level 14, Melbourne, VIC, AU
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Peter Laurence Molloy
- Headquarters
- Level 14, Melbourne, VIC, AU
Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Australian market.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Firebrick Pharma Limited. Starting points for Firebrick Pharma Limited: EPS -AUD 0.01, beta 0.85 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Firebrick Pharma Limited. Firebrick Pharma Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Firebrick Pharma Limited. Trailing twelve-month EPS for Firebrick Pharma Limited stands at -AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Firebrick Pharma Limited. Firebrick Pharma Limited has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| AVE.AXAvecho Biotechnology Limited | Healthcare | Biotechnology | — | ||
| BTC.AXBTC Health Limited | Healthcare | Biotechnology | — | ||
| IMC.AXImmuron Limited | Healthcare | Biotechnology | — | ||
| IME.AXImExHS Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| NC6.AXNanollose Limited | Healthcare | Biotechnology | — | ||
| NTI.AXNeurotech International Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| SNYSanofi | Healthcare | NASDAQ | $113.1B | ||
| SNYNFSanofi | Healthcare | OTC | $115.1B | ||
| TGRNFTong Ren Tang Technologies Co. Ltd. | Healthcare | OTC | $704.4M | ||
| VRBCFVirbac S.A. | Healthcare | OTC | $2.9B | ||
| ABBVAbbVie Inc. | Healthcare | NYSE | $505.5B | ||
| ALPMFAstellas Pharma Inc. | Healthcare | OTC | $28.1B | ||
| ALPMYAstellas Pharma Inc. | Healthcare | OTC | $29.2B | ||
| AMGNAmgen Inc. | Healthcare | NASDAQ | $240.1B | ||
| AMRNAmarin Corporation plc | Healthcare | NASDAQ | $232.9M | ||
| AZNAstraZeneca PLC | Healthcare | NYSE | $277.2B | ||
| BAYRYBayer AG | Healthcare | OTC | $49.0B | ||
| BIIBBiogen Inc. | Healthcare | NASDAQ | $37.2B | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Firebrick Pharma Limited.